|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Shares of both are lower after two patients die while taking the drug.
The company says it will take 'several quarters' before it can assess the prospects for Tysabri.
The drug helps maintain remission in patients who were treated for longer than two years.
The drug also improves the cognitive function of multiple sclerosis patients.
The company and Transition Therapeutics are collaborating to develop a new treatment.
Deborah Knobelman says the drug's U.S. sales this year will likely be much lower than she expected.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.